DHR SEC Filings

Danaher Corporation (DHR) announced its entry into a definitive Agreement and Plan of Merger to acquire Masimo Corporation (MASI) for $180.00 per share in cash. This acquisition, structured as a merger where Masimo will become a wholly owned subsidiary of Danaher, represents a significant strategic move for Danaher. The transaction is subject to customary closing conditions, including antitrust approvals under the Hart-Scott-Rodino Act and certain non-U.S. regulatory clearances. Investors should note that this filing serves as an initial announcement of the merger agreement. Further details regarding the transaction, including the proxy statement to be filed by Masimo, will be crucial for a complete understanding of the deal's implications. Both companies have provided extensive disclosures regarding potential participants in the solicitation process and cautionary statements concerning forward-looking information, highlighting the inherent risks and uncertainties associated with the transaction's completion and its anticipated benefits.

Danaher Corporation (DHR) announced a change to its Board of Directors with the retirement of Jessica L. Mega, effective February 5, 2026. Dr. Mega's departure is attributed to increasing commitments from her other professional endeavors and is not a reflection of any disagreements with the company's operations, policies, or practices. This event, while noted, does not appear to signal any material operational or strategic shifts for Danaher at this time, but investors should monitor board composition for any long-term implications. The filing also includes the standard XBRL interactive data file. Investors should consider this an administrative update concerning board membership rather than a primary driver of near-term stock performance. The company continues its focus on its core business segments, and the absence of Dr. Mega from the board is not expected to impact the company's strategic direction or financial performance.

Danaher Corporation (DHR) has filed an 8-K report on January 28, 2026, announcing its financial results for the year ended December 31, 2025. The report primarily serves to furnish a press release detailing these results, which is incorporated by reference as Exhibit 99.1. Investors should note that this information, while informative, is furnished and not deemed "filed" under Section 18 of the Securities Exchange Act of 1934, unless specifically incorporated into a future filing. The key takeaway for investors is that this filing provides the official announcement of Danaher's performance for the full fiscal year 2025, including fourth-quarter results. While the 8-K itself does not contain the financial data, it directs readers to the accompanying press release for the comprehensive details on revenue, profitability, and other key financial metrics. Investors are encouraged to review Exhibit 99.1 for a thorough understanding of the company's operational and financial condition.

Danaher Corporation (DHR) has filed a Current Report (8-K) on January 12, 2026, providing an early look at its estimated financial performance for the fourth quarter of 2025. This release is in anticipation of the company's participation in the J.P. Morgan Healthcare Conference scheduled for January 13, 2026. While specific financial figures are not detailed within the 8-K itself, the filing incorporates by reference a press release and presentation slides that contain this estimated performance data. Investors should note that this information is furnished and not deemed "filed" under Section 18 of the Exchange Act, meaning it carries a different legal implication than a standard filing. The attached exhibits, including the press release and presentation slides, are the primary sources for understanding Danaher's preliminary Q4 2025 and full-year 2025 financial outlook. These documents are crucial for investors to assess the company's recent operational results and financial condition ahead of the J.P. Morgan conference.

Danaher Corporation (DHR) has filed a Current Report (8-K) primarily detailing a change in its Board of Directors. John T. Schwieters has informed the Board of his decision not to seek reelection at the upcoming 2026 annual meeting of shareholders, leading to his retirement from the Board at that time. Importantly, this decision is not attributed to any disagreements with the company regarding its operations, policies, or practices, which suggests a smooth transition and continued stable governance. As a consequence of Mr. Schwieters' retirement, the size of the Danaher Board will be reduced from thirteen to twelve members following his departure. This structural adjustment is a notable point for investors to consider regarding board composition and governance. The filing also includes the standard interactive data file exhibit.

Danaher Corporation's (DHR) third quarter 2025 report shows a solid performance with overall revenues increasing by 4.5% and core sales by 3.0% year-over-year. The company continues to experience growth in its Biotechnology and Diagnostics segments, which more than offset a slight decline in Life Sciences. Despite a challenging global economic and geopolitical environment, including impacts from tariffs and potential government shutdowns, Danaher demonstrates resilience through its diversified business model and strategic focus on innovation and cost efficiency. The company maintained healthy operating profit margins, though overall net earnings for the nine-month period were impacted by significant impairment charges and investment losses compared to the prior year. Looking ahead, Danaher faces uncertainties related to trade policies, regulatory changes, and geopolitical events, but remains committed to strategic investments and operational improvements. The company's liquidity position appears strong, with substantial cash generated from operations, supporting its ongoing capital allocation strategies including dividends and share repurchases. Investors should monitor the company's ability to navigate trade-related cost increases and sustain growth in its key segments.

Danaher Corporation (DHR) has filed a Current Report on Form 8-K on October 21, 2025, to announce its financial results for the third quarter ended September 26, 2025. The report primarily serves to furnish a press release containing these results, which is incorporated by reference. Investors should note that this information is furnished and not deemed "filed" for purposes of certain securities regulations, unless expressly incorporated by reference in a future filing. The full details of the financial performance are available in the press release (Exhibit 99.1) attached to this filing.

Danaher Corporation (DHR) filed an 8-K on September 9, 2025, announcing two significant updates for its shareholders. First, the company's Board of Directors amended and restated the corporate By-laws, primarily focusing on revising the procedural and disclosure requirements for shareholders wishing to propose business or nominate directors at meetings. These changes are designed to streamline the process and ensure timely and adequate information sharing. Second, and more materially for investors, Danaher's Board approved a substantial new share repurchase program. This program authorizes the repurchase of up to 35 million shares of common stock, which can be executed through various methods including open market purchases and Rule 10b5-1 trading plans. This significant buyback authorization, which has no expiration date, signals management's confidence in the company's valuation and commitment to returning capital to shareholders.

Danaher Corporation (DHR) has filed an 8-K report disclosing a significant leadership transition within its legal department. Brian W. Ellis, Senior Vice President and General Counsel, has announced his intention to step down from his General Counsel role effective August 25, 2025. While relinquishing his primary legal leadership responsibilities, Mr. Ellis will remain with the company in an executive officer capacity as Senior Vice President, supporting the company until his planned retirement on February 28, 2026. This announcement marks a key change in Danaher's executive team. Investors should note that Mr. Ellis's continued involvement in a Senior Vice President role, albeit with a different focus, indicates a phased transition rather than an immediate departure. The company has not yet announced a successor for the General Counsel position, which will be a point of interest for stakeholders monitoring leadership continuity and strategic direction within Danaher's legal and executive functions.

Danaher Corporation (DHR) has announced a planned transition for its Chief Financial Officer role. Matthew M. McGrew, the current Executive Vice President and CFO, will relinquish his CFO duties effective February 28, 2026, and will continue with the company as an Executive Vice President. Succeeding Mr. McGrew will be Matthew E. Gugino, who currently serves as Danaher’s Vice President-Corporate FP&A and Group CFO. This transition signals a long-term succession plan for a key executive position within the company. In connection with this transition, Mr. Gugino's compensation has been adjusted to reflect his new responsibilities. This includes an immediate increase in base salary and bonus target, followed by further increases and significant equity awards effective upon his formal appointment as CFO in February 2026. The compensation adjustments are designed to align with the increased scope and importance of the CFO role. Mr. McGrew's compensation will also be adjusted as he moves into his continued executive role.

Danaher Corporation reported mixed results for the second quarter of 2025. Overall revenues saw a modest increase of 3.5% year-over-year, driven by a 2.0% contribution from currency exchange rates and 1.5% from core sales. However, net earnings and diluted earnings per share experienced a significant decline compared to the prior year, primarily due to a substantial impairment charge of $432 million related to a trade name in the Life Sciences segment. While the Biotechnology segment showed robust growth with an 8.0% increase in total sales (6.0% core sales growth), the Life Sciences segment experienced a 2.5% decline in core sales, and the Diagnostics segment saw flat core sales growth for the six-month period. Operating profit margins were negatively impacted by the aforementioned impairment charge and the dilutive effect of recent acquisitions. Despite these challenges, Danaher's liquidity remains strong, with $3.0 billion in cash and cash equivalents. The company continues to generate significant operating cash flow, though it decreased by 16% year-over-year for the first six months of 2025, largely due to lower net earnings and increased non-cash charges. The company is actively managing its capital structure, with a reduced pace of share repurchases in the current period compared to the previous year and an increase in dividend payments.

Danaher Corporation (DHR) filed an 8-K on July 22, 2025, to announce its financial results for the second quarter ended June 27, 2025. The report itself is a notification of the release of this information, with the detailed financial performance disclosed in a press release furnished as Exhibit 99.1. Investors should refer to this press release for comprehensive details on revenue, earnings, and segment performance. This filing is crucial for understanding Danaher's recent operational and financial standing. The market will be closely scrutinizing these results to gauge the company's trajectory, particularly in light of its diverse business segments. While the 8-K itself does not contain the figures, its purpose is to formally alert the public and the market to the availability of the Q2 2025 financial performance data, enabling investors to make informed decisions.

Danaher Corporation (DHR) filed an 8-K on May 7, 2025, detailing the results of its annual shareholder meeting held on May 6, 2025. The primary focus of the filing is the voting outcomes on key corporate governance and operational matters. All thirteen director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board leadership. Shareholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, a standard procedure that reinforces oversight of financial reporting. Furthermore, the advisory vote on the compensation of the Company's named executive officers received majority approval. While the specific compensation details are not within this 8-K, the positive vote suggests shareholder satisfaction with the executive compensation structure. The filing also includes the standard Cover Page Interactive Data File in XBRL format, facilitating easier access to financial data for investors and analysts.

Danaher Corporation (DHR) reported its first quarter 2025 results, indicating a slight overall revenue decrease of 1.0% year-over-year, with core sales remaining flat. This performance was influenced by varied segment contributions, with the Biotechnology segment showing robust growth while Life Sciences and Diagnostics experienced declines. Net earnings also saw a reduction compared to the prior year, attributed to increased operating expenses, investment losses, and net interest expense. The company is navigating a challenging macroeconomic environment, including the impact of new tariffs, which are expected to add several hundred million dollars in costs, though Danaher aims to offset these through operational adjustments. Despite the top-line softness, Danaher continues to invest in growth and manage its capital effectively. The company repurchased approximately $1.1 billion of its common stock in the quarter and increased its quarterly dividend. The Biotechnology segment demonstrated strong operating profit margin expansion, driven by higher core sales and improved cost structures. However, the Life Sciences and Diagnostics segments faced margin pressures due to lower core sales and specific business mix impacts. Investors should monitor the company's ability to mitigate tariff impacts and drive growth across all segments, particularly in China where certain market dynamics are challenging.

Danaher Corporation (DHR) filed an 8-K on April 22, 2025, to announce its financial results for the first quarter ended March 28, 2025. The report references a press release (Exhibit 99.1) which contains the detailed financial and operational performance for the period. Investors should refer to this press release for comprehensive information regarding the company's performance, including revenue, earnings, and any forward-looking guidance or strategic updates. This filing serves as the official notification of these quarterly results. While the 8-K itself is brief and primarily an informational filing, it triggers the public dissemination of important financial data. The furnished press release is expected to provide insights into Danaher's business segments, key performance indicators, and management's commentary on the current operating environment and outlook. Investors are encouraged to review Exhibit 99.1 for a complete understanding of Danaher's Q1 2025 financial standing and future expectations.

Danaher Corporation (DHR) reported flat total sales for the fiscal year ended December 30, 2024, with a 1.5% decrease in core sales. This performance was influenced by a 2.0% boost from acquisitions, which partially offset declines in the Biotechnology and Life Sciences segments, while the Diagnostics segment showed growth. Net earnings from continuing operations declined to $3.9 billion from $4.2 billion in the prior year, impacted by intangible asset impairments and increased operating expenses. The company's strategic priorities remain focused on strengthening competitive advantage through the Danaher Business System (DBS), enhancing its portfolio via strategic capital allocation, and attracting top talent. Looking ahead, Danaher has initiated a cost savings program expected to generate at least $150 million in annual pre-tax savings starting in Q1 2025. The company also continues to manage its capital structure, evidenced by significant share repurchases totaling $6.0 billion in 2024. Despite a challenging macro-economic environment, including global economic uncertainty and inflationary pressures, Danaher's diversified business model across life sciences, diagnostics, and biotechnology sectors provides a degree of resilience.

Danaher Corporation (DHR) filed an 8-K report on February 20, 2025, announcing two key updates: the appointment of a new independent director and an amendment to its 2007 Omnibus Incentive Plan. Charles W. Lamanna has joined the Board of Directors and will serve on the Science & Technology Committee. His appointment is considered independent and he will receive standard compensation for non-employee directors, including equity awards. The second significant development involves an amendment to the Company's 2007 Omnibus Incentive Plan. This amendment enhances benefits for participants whose employment or service terminates due to death or disability. Specifically, unvested stock options and restricted stock units will now fully vest, and performance stock units (PSUs) will vest at the target level if the termination event occurs before the performance period concludes. These changes aim to provide greater financial security to key personnel and their estates in the event of unforeseen circumstances.

Danaher Corporation (DHR) filed an 8-K on January 29, 2025, to announce its financial results for the year ended December 31, 2024. The primary purpose of this filing is to furnish the accompanying press release, which details the company's performance for the fourth quarter and the full year of 2024. Investors should refer to the press release (Exhibit 99.1) for specific financial metrics, operational performance commentary, and forward-looking statements. While this 8-K itself does not contain detailed financial tables or management discussion, it serves as the official notification that the earnings release is now publicly available. This is a standard procedure for reporting quarterly and annual results. Investors seeking a comprehensive understanding of DHR's financial condition, profitability, and any strategic updates should carefully review the provided press release for quantitative data and qualitative insights into the company's business segments and outlook.

Danaher Corporation (DHR) has filed an 8-K report to provide advance commentary on its estimated financial performance for the fourth quarter of 2024. This update is being released in anticipation of their participation in the J.P. Morgan Healthcare Conference on January 14, 2025. While the specific financial figures are not detailed within the 8-K itself, the filing incorporates by reference a press release and accompanying presentation slides that contain this forward-looking information. Investors should monitor the webcast and the furnished materials for key performance indicators, revenue trends, and any strategic outlook for the upcoming periods. This proactive communication aims to provide stakeholders with a preview of the company's recent performance before the official earnings release, potentially impacting short-term market sentiment and investor expectations.

Danaher Corporation (DHR) announced on December 10, 2024, the retirement of Dr. Pardis C. Sabeti from its Board of Directors, effective the same date. This departure is attributed to Dr. Sabeti's existing professional commitments and is explicitly stated as not being the result of any disagreement with the company. Investors should note that this change on the Board does not appear to be linked to any operational or strategic issues within Danaher. The filing also includes the standard cover page interactive data file as an exhibit. For investors, the primary takeaway is the smooth transition regarding Dr. Sabeti's board seat, maintaining stability within the company's governance structure. No financial statements or material business updates were disclosed in this particular 8-K filing, suggesting it is primarily administrative in nature.

Danaher Corporation's Q3 2024 Form 10-Q filing indicates a mixed performance across its segments, with overall revenues seeing a 3.0% increase year-over-year, driven by acquisitions and price increases, while core sales grew by a modest 0.5%. The Diagnostics segment was a key performer, demonstrating strong core sales growth. However, the Life Sciences and Biotechnology segments experienced core sales declines, with Life Sciences impacted by an impairment charge and increased acquisition dilution, and Biotechnology facing reduced demand and inventory rationalization from larger customers. Net earnings from continuing operations saw a year-over-year decline, impacted by intangible asset impairments and increased operating expenses. The company generated substantial operating cash flow, though it decreased compared to the prior year, largely due to lower net earnings and changes in working capital. Significant cash outflow was observed in financing activities, primarily driven by substantial share repurchases, alongside debt repayments. Danaher maintains a strong liquidity position with significant cash on hand, and expects its effective tax rate for the remainder of 2024 to be around 17.5%.

Danaher Corporation (DHR) filed an 8-K on October 22, 2024, to report its financial results for the third quarter ended September 27, 2024. The filing includes a press release detailing these results, which is furnished as an exhibit and incorporated by reference. Investors should review this press release for specific operational and financial performance metrics, including revenue, earnings, and any forward-looking guidance provided by the company. This report is crucial for understanding Danaher's recent performance and its implications for future financial periods. While the 8-K itself is a formal notification, the substance of the financial results, as presented in the accompanying press release, will contain the key data points investors need to assess the company's ongoing strategy and market position. It's important to note that this information is furnished, not filed, under Section 18 of the Exchange Act, meaning it has less formal regulatory implication for past disclosures but is still critical for understanding current performance.

Danaher Corporation (DHR) filed an 8-K on July 23, 2024, to announce its financial results for the second quarter ended June 28, 2024. The filing primarily serves to furnish a press release detailing these results, which is incorporated by reference. Investors should refer to the press release (Exhibit 99.1) for comprehensive details on the company's performance during the quarter. It's important to note that this information is furnished and not deemed "filed" for purposes of certain sections of the Securities Exchange Act of 1934, unless specifically incorporated by reference into other filings.

Danaher Corporation reported a 3.0% decrease in overall revenues for the second quarter of 2024 compared to the prior year, with core sales down 3.5%. This decline was primarily driven by weaker performance in the Biotechnology and Life Sciences segments, particularly in high-growth markets like China. Conversely, the Diagnostics segment showed resilience with increased core sales, led by North America. The company's net earnings from continuing operations also saw a year-over-year decrease, reflecting lower sales and increased other expenses. Despite the revenue headwinds, Danaher's gross profit margin improved due to lower cost of sales and the benefit from the Abcam acquisition. For the first six months of 2024, the trend of declining revenues and core sales continued, mirroring the quarterly performance. Operating profit margins across segments showed mixed results, with significant decreases in Life Sciences and Biotechnology, while Diagnostics saw substantial improvement. The company generated strong operating cash flows but utilized a significant portion for substantial stock repurchases during the period. Danaher maintained its focus on strategic investments and managing its capital structure, with liquidity expected to remain sufficient.

Danaher Corporation (DHR) has filed an 8-K report to disclose the departure of Joakim Weidemanis from his role as Executive Vice President, effective July 1, 2024. Mr. Weidemanis will continue to be employed by Danaher through September 30, 2024, to provide transition services, ensuring a smooth handover of his responsibilities. This filing outlines the terms of his transition, including continued salary and a pro-rated incentive compensation award for 2024, contingent on certain performance factors and a release of claims. While the departure of a key executive can sometimes raise investor concerns, Danaher's proactive approach in securing transition services and detailing the compensation terms aims to mitigate disruption. Investors should monitor the company's performance and strategic execution in the coming quarters, particularly in areas previously overseen by Mr. Weidemanis, to assess any potential impact on the business. The filing also includes the Transition Agreement as an exhibit, providing transparency on the executive's departure terms.

Danaher Corporation (DHR) filed an 8-K on May 8, 2024, detailing the results of its annual shareholder meeting held on May 7, 2024. The primary focus of this filing is the voting outcomes on several key proposals. Notably, all thirteen director nominees were elected, and shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the upcoming fiscal year. The advisory vote on executive compensation also received shareholder approval.

Danaher Corporation (DHR) filed an 8-K on April 23, 2024, to report its financial results for the first quarter ended March 29, 2024. The key information is contained within the press release furnished as Exhibit 99.1, which details the company's performance during the period. Investors should review this press release for specific figures related to revenue, earnings, and other operational and financial conditions. This filing serves as notification of the release of DHR's Q1 2024 financial outcomes. While the 8-K itself provides the procedural context, the actual substance of the financial results, including any forward-looking statements or management commentary on performance drivers and outlook, is found in the attached press release. Therefore, the press release is the primary document for investors seeking to understand Danaher's most recent financial standing.

Danaher Corporation reported a decrease in total sales of 2.5% for the first quarter of 2024 compared to the same period in 2023, with core sales declining by 4.0%. This was primarily driven by a significant drop in the Biotechnology segment, particularly in bioprocessing due to lower customer inventory levels and a tighter credit environment affecting emerging companies. The Diagnostics segment showed resilience with 6.5% total sales growth and 7.5% core sales growth, driven by molecular and clinical diagnostics. The Life Sciences segment experienced a slight 2.0% total sales increase, impacted by acquisitions, but saw a 3.0% decline in core sales due to weaker demand in pharmaceutical and biopharmaceutical customers. Net earnings from continuing operations also declined year-over-year, impacted by the lower core sales and a dilutive effect from recent acquisitions, including a fair value adjustment related to Abcam. The company's liquidity remains strong, with $7.0 billion in cash and cash equivalents as of March 29, 2024, and sufficient operating cash flow to meet its financial obligations, including investments, debt servicing, dividends, and potential acquisitions. Management anticipates the challenging demand in bioprocessing to continue into the second quarter, with gradual improvement expected through the year.

Danaher Corporation (DHR) reported a decrease in total sales and net earnings for the fiscal year ended December 31, 2023, compared to the previous year. This decline was primarily driven by a significant reduction in demand for COVID-19 related products and a general slowdown in certain end markets. The company's core sales also saw a notable decrease. Despite the overall revenue decline, Danaher continued to execute its strategic priorities, including the significant acquisition of Abcam plc for $5.6 billion, strengthening its Life Sciences segment. The company also completed the separation of its former Environmental & Applied Solutions business into Veralto Corporation. Danaher's diversified business segments—Biotechnology, Life Sciences, and Diagnostics—face varying market dynamics, with Biotechnology experiencing the most pronounced sales decrease due to the normalization of COVID-19 related demand. The company remains focused on innovation, operational efficiency through its Danaher Business System (DBS), and strategic capital allocation for long-term shareholder value creation.

Danaher Corporation (DHR) filed an 8-K on February 14, 2024, to announce a significant change in its Board of Directors. Walter G. Lohr, Jr., a long-standing member of the Board, has decided not to seek reelection at the upcoming annual meeting of shareholders on May 7, 2024. He will officially retire from the Board at that time. Importantly, the filing clarifies that Mr. Lohr's decision is voluntary and not due to any disputes or disagreements with the company regarding its operations, policies, or practices.

Danaher Corporation filed an 8-K on January 30, 2024, to announce its financial results for the year ended December 31, 2023. The filing primarily comprises a press release detailing these results, which investors should review for a comprehensive understanding of the company's performance. This report serves as notification of the release of the financial information and does not represent a material event beyond the earnings announcement itself. Investors interested in Danaher's performance for the fourth quarter and full year 2023 should refer to the furnished press release (Exhibit 99.1). While this 8-K does not contain a deep dive into the financial metrics, it officially flags the availability of the earnings report. The information is furnished, not filed, under Section 18 of the Exchange Act, meaning it doesn't automatically become part of the company's official SEC filings unless specifically incorporated by reference.

Danaher Corporation (DHR) filed an 8-K on January 8, 2024, to provide a preview of its anticipated financial performance for the fourth quarter of 2023, ahead of its presentation at the J.P. Morgan Healthcare Conference. The filing includes a press release and presentation slides, which are incorporated by reference. Investors should note that this information is furnished and not formally "filed" under Section 18 of the Exchange Act, meaning it does not automatically update previous filings unless explicitly referenced.

Danaher Corporation (DHR) has filed an 8-K report on October 24, 2023, to announce its financial results for the third quarter ended September 29, 2023. The report primarily directs investors to a furnished press release (Exhibit 99.1) which contains the detailed financial performance and operational updates for the period. Investors should refer to this press release for specific figures, including revenue, earnings, and any forward-looking guidance provided by the company. This filing serves as the official notification of the company's quarterly performance. While the 8-K itself is brief, the accompanying press release is crucial for understanding Danaher's financial condition, operational highlights, and management's commentary on the business environment and future outlook. Investors are advised to review Exhibit 99.1 for a comprehensive understanding of the reported results and their implications.

Danaher Corporation's Q3 2023 report indicates a challenging quarter with a 10.5% decrease in overall revenue and an 11.5% decline in core sales year-over-year. This decline is primarily attributed to a significant drop in demand for COVID-19 related products across its Biotechnology and Diagnostics segments, compounded by reduced activity in high-growth markets like China. Despite these headwinds, the company is strategically positioning itself for the future with the pending acquisition of Abcam plc for approximately $5.7 billion, which is expected to bolster its Life Sciences segment. The company also completed the separation of its Environmental & Applied Solutions business into Veralto Corporation, effective September 30, 2023. This strategic move is intended to allow Danaher to focus on its core life sciences and diagnostics businesses. While revenue and operating profit margins saw a decline, the company maintains a strong liquidity position with $12.3 billion in cash and cash equivalents as of September 29, 2023, and remains committed to strategic investments and shareholder returns through dividends and share repurchases.

Danaher Corporation (DHR) filed an 8-K on October 2, 2023, to announce the completion of the separation and distribution of its wholly owned subsidiary, Veralto Corporation, into a separate publicly traded company. This significant event, effective September 29, 2023, involved a series of definitive agreements that formally establish the terms of the separation, the ongoing relationship between Danaher and Veralto, and the allocation of assets, employees, and liabilities. Key agreements include the Separation and Distribution Agreement, Employee Matters Agreement, Tax Matters Agreement, Transition Services Agreement, Intellectual Property Matters Agreement, DBS License Agreement, and a Framework Agreement. These documents provide clarity on how the two entities will operate independently while outlining provisions for shared services, intellectual property licensing, and tax responsibilities. Investors should note that Veralto is now operating as a standalone entity, and its future performance will be distinct from Danaher's.

Danaher Corporation (DHR) has announced a significant financing transaction through its wholly-owned subsidiary, Veralto Corporation. Veralto has issued a substantial amount of senior notes in both U.S. dollar and Euro denominations, totaling $2.1 billion and €500 million respectively. These notes are intended to fund the upcoming separation of Veralto from Danaher, a spin-off event anticipated by investors. Danaher has provided full and unconditional guarantees for these notes, which will be released upon the completion of the Veralto separation.

This 8-K filing from Danaher Corporation (DHR) details significant debt offerings by its subsidiary, Veralto Corporation, in preparation for Veralto's planned separation from Danaher. Veralto has agreed to issue a substantial amount of senior notes denominated in both USD and EUR, totaling approximately $2.1 billion and €500 million respectively, with various maturity dates and interest rates. These offerings are crucial for financing the separation and providing Veralto with its own capital structure as it prepares to operate as an independent entity. Danaher will guarantee these notes until the separation is complete, after which Veralto will be solely responsible. The proceeds from these offerings will be used by Veralto to make payments to Danaher as partial consideration for the assets contributed during the separation, as well as to cover associated fees and expenses. Investors should note that these notes are being sold in private placements to qualified institutional buyers and non-U.S. persons, and Veralto intends to register similar notes later to facilitate resales.

Danaher Corporation (DHR) has filed an 8-K report to inform investors about a temporary trading suspension, commonly known as a "blackout period," affecting its employee benefit plans. This blackout is a direct consequence of the upcoming separation of Veralto Corporation from Danaher, which is scheduled for September 30, 2023. During this period, participants in various Danaher savings and deferred compensation plans will be unable to exercise certain rights related to the Danaher Stock Fund. The blackout period is specifically designed to comply with regulations such as Section 306(a) of the Sarbanes-Oxley Act and Regulation BTR. It will restrict Danaher's directors and Section 16 officers from trading Danaher common stock or related derivative securities during the blackout. This measure is standard procedure when a significant corporate event, like a spin-off, impacts employee stock plans and trading restrictions are necessitated.

Danaher Corporation (DHR) has filed an 8-K report to disclose the entry into a material definitive agreement concerning a new credit facility. This report details a $1.5 billion unsecured five-year credit facility secured by its wholly-owned subsidiary, Veralto Corporation. The facility, effective August 31, 2023, with a maturity date of August 31, 2028, provides Veralto with significant liquidity and flexibility. The credit facility includes provisions for an extension option and an expansion option of up to $500 million, indicating potential future financing needs or growth opportunities. The terms of the facility establish interest rate mechanisms tied to Veralto's credit rating and include a facility fee. Crucially, Veralto is required to maintain a specific Consolidated Net Leverage Ratio, with a temporary increase allowed following significant acquisitions. This facility is intended to support Veralto's commercial paper program and general corporate purposes, and borrowings are contingent upon the completion of the previously announced separation of Danaher's Environmental & Applied Solutions business into Veralto.

Danaher Corporation (DHR) has entered into a new $5.0 billion unsecured, multiyear revolving credit facility, replacing its previous agreement. This new facility, set to expire on August 11, 2028, includes a one-year extension option and an expansion option allowing for an additional $2.5 billion in borrowings, subject to certain conditions. The credit facility is intended to provide liquidity support for Danaher's commercial paper programs and for general corporate purposes, indicating a focus on maintaining operational flexibility and financial stability. The terms of the credit facility include variable interest rates tied to credit ratings and benchmark rates like Term SOFR. A key financial covenant requires Danaher to maintain a Consolidated Leverage Ratio of 0.65 to 1.00 or less, demonstrating a commitment to prudent financial management and a healthy balance sheet. While unsecured, the facility includes customary covenants and events of default, with potential acceleration of debt upon default. The establishment of this facility provides Danaher with robust financial resources to manage its ongoing operations and potential future strategic initiatives.

Danaher Corporation (DHR) filed an 8-K on July 25, 2023, to announce its financial results for the second quarter ended June 30, 2023. The company furnished a press release detailing these results, which is incorporated by reference into the filing. Investors should note that this information, while publicly disclosed, is furnished and not deemed 'filed' for the purposes of Section 18 of the Exchange Act, unless specifically incorporated by reference in a future filing. The key takeaway for investors is the announcement of Q2 2023 financial performance, with further details available in the furnished press release.

Danaher Corporation reported a 7.5% decrease in total revenue for the second quarter of 2023 compared to the prior year, with core sales down 7.0%. This decline was primarily driven by reduced demand for COVID-19 related products across its Biotechnology and Diagnostics segments, as well as a significant drop in China's Biotechnology segment due to a deteriorating funding environment. Despite the revenue headwinds, the company continues to generate substantial operating cash flow, with $3.9 billion for the first six months of 2023. Danaher is also progressing with its plan to separate its Environmental & Applied Solutions (EAS) segment into a new publicly traded company, Veralto Corporation, expected in the fourth quarter of 2023. While the overall revenue picture shows a year-over-year decline, it's important to note that price increases contributed positively to sales, partially offsetting volume declines. The company is actively managing its cost structure in response to changing demand, particularly in its Diagnostics and Biotechnology segments. Investors should monitor the impact of the EAS separation, ongoing demand normalization post-COVID, and the broader economic environment on future performance.

Danaher Corporation (DHR) has filed an 8-K detailing the elimination of its Series A and Series B Mandatory Convertible Preferred Stock following their complete conversion. This action formalizes the cessation of these preferred stock series, as no outstanding shares remained after their mandatory conversion dates in April 2022 and April 2023, respectively. This corporate housekeeping item simplifies the company's capital structure by removing these instruments from its charter. Additionally, the filing reports on the outcomes of Danaher's annual shareholder meeting held on May 9, 2023. Key to investors, all nominated directors were overwhelmingly elected, and the company's selection of Ernst & Young LLP as its independent auditor for 2023 was ratified with strong shareholder support. Shareholder approval was also given for executive compensation on an advisory basis, with a clear preference for annual advisory votes on this matter. Notably, shareholder proposals requesting the separation of Chair and CEO roles and a report on DEI efforts were not approved.

Danaher Corporation reported a 7.0% decrease in total sales for the first quarter of 2023 compared to the prior year, with core sales down 4.0%. This decline was primarily driven by reduced demand for COVID-19 related products, particularly in the Biotechnology and Diagnostics segments, as well as the impact of unfavorable currency exchange rates. Net earnings attributable to common stockholders were $1.4 billion, or $1.94 per diluted share, down from $1.7 billion, or $2.31 per diluted share, in the first quarter of 2022. Despite the overall sales decrease, the Environmental & Applied Solutions segment showed a 5.0% increase in total sales, driven by strong performance in its water quality businesses. The company is progressing with its plan to separate the Environmental & Applied Solutions segment into a new publicly traded company, Veralto Corporation, in the fourth quarter of 2023. Danaher maintains a strong liquidity position with $7.4 billion in cash and cash equivalents as of March 31, 2023, and continues to generate substantial operating cash flow, which management believes is sufficient to fund operations, acquisitions, and shareholder returns.

Danaher Corporation (DHR) filed an 8-K on April 25, 2023, to report its first quarter 2023 financial results. The filing primarily includes a press release announcing these results, which is incorporated by reference. While the 8-K itself doesn't contain the detailed financial tables or operational commentary, it serves as the official notification to the market that these results have been disseminated. Investors should refer to the furnished press release (Exhibit 99.1) for specific financial performance metrics, segment details, and management's outlook.

Danaher Corporation reported solid performance for the fiscal year ending December 31, 2022, demonstrating resilience amidst economic uncertainties and supply chain challenges. The company achieved total sales growth of 7.0%, driven by a 9.5% increase in core sales, indicating strong underlying business performance. Net earnings from continuing operations rose to $7.2 billion, up from $6.3 billion in the prior year. The company's diverse segment structure, encompassing Biotechnology, Life Sciences, Diagnostics, and Environmental & Applied Solutions, contributed to this growth, with strong performance noted across several key areas, including molecular diagnostics and bioprocessing. Danaher also reaffirmed its commitment to strategic capital allocation and operational excellence through the Danaher Business System (DBS). Looking ahead, Danaher announced its intention to separate its Environmental & Applied Solutions (EAS) segment into a standalone publicly traded company in the fourth quarter of 2023, a move expected to unlock further value. Despite facing headwinds such as supply chain disruptions and inflation, which were largely mitigated through DBS, the company's strategic focus on innovation, customer service, and attracting top talent positions it well for continued growth and value creation. Investors should note the ongoing management of global operations and adaptation to market dynamics, including the impact of foreign currency fluctuations.

Danaher Corporation (DHR) filed an 8-K on January 24, 2023, to announce its financial results for the year ended December 31, 2022. The report primarily directs investors to a press release (Exhibit 99.1) which contains the detailed financial outcomes. While the 8-K itself doesn't provide the numbers, it signifies the official disclosure of the company's performance for the fourth quarter and the full fiscal year 2022. Investors should consult the furnished press release for specific revenue, earnings, and other key financial metrics.

Danaher Corporation (DHR) has announced a change in its reportable business segments, effective for its fourth quarter of 2022 results. Previously operating under three segments (Life Sciences, Diagnostics, and Environmental & Applied Solutions), the company is now realigning its structure into four segments: Biotechnology, Life Sciences, Diagnostics, and Environmental & Applied Solutions. This change is driven by the growth within certain businesses previously housed in the Life Sciences segment, leading to the creation of a distinct Biotechnology segment. The recast historical financial data reflecting this new structure is available on Danaher's investor relations website, and the upcoming Form 10-K for the year ended December 31, 2022, will also incorporate these changes. This segment realignment is a retrospective change and does not alter previously filed financial statements like Consolidated Statements of Earnings, Balance Sheets, or Cash Flows. The primary impact for investors is a clearer view of the performance and contributions of the newly defined Biotechnology segment, which encompasses bioprocessing and discovery and medical businesses, alongside the redefined Life Sciences segment, which will now include flow cytometry, genomics, lab automation, mass spectrometry, microscopy, industrial filtration, and genomic consumables. The Diagnostics and Environmental & Applied Solutions segments remain unchanged.

Danaher Corporation (DHR) filed an 8-K on January 9, 2023, to furnish a press release and presentation slides ahead of their J.P. Morgan Healthcare Conference appearance on January 10, 2023. These documents provide insights into the company's anticipated financial performance for the fourth quarter and full year 2022. While specific financial figures are not detailed within the 8-K text itself, the furnished materials are expected to offer guidance and commentary on key operational and financial metrics, including revenue, earnings, and potentially divisional performance. Investors should review the referenced press release and presentation slides for detailed financial expectations and strategic outlook.

Danaher Corporation (DHR) filed an 8-K on December 6, 2022, primarily to report amendments to its Amended and Restated By-laws, effective December 5, 2022. These changes focus on revising the advance notice and procedural requirements for shareholders wishing to propose business or nominate directors at shareholder meetings. This update aims to streamline and clarify the process for shareholder engagement in corporate governance matters. While this filing does not contain significant financial updates or operational changes, investors should note the modifications to the by-laws. These amendments are important for understanding the procedures required for shareholders to exercise their rights in proposing matters or nominating candidates for the Board of Directors. The company has also included routine, non-substantive updates to the by-laws.